MedTrace Logo

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

NCT03794076 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-03-19

No results posted yet for this study

Summary

This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.

Conditions

Interventions

DRUG

Cromoglycate

Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray

DRUG

Placebo

Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Vishwajit Nimgaonkar, MD PhD

    lead OTHER

Principal Investigators

  • Vishwajit L. Nimgaonkar, M.D., Ph.D. · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2028-01-31
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03794076 on ClinicalTrials.gov